Robert W Holloway
Overview
Explore the profile of Robert W Holloway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Awada A, Recio F, Kuhn T, Ahmad S, Zhu J, McKenzie N, et al.
Gynecol Oncol Rep
. 2025 Feb;
57:101684.
PMID: 39944179
Objective: To compare clinical outcomes of patients with early-stage, high-intermediate risk (HIR) endometrial cancer (EC) and isolated tumor cells (ITC) lymph node metastases treated with chemotherapy/radiotherapy (CRT) vs. external beam...
2.
Kilowski K, Dietrich M, Xiu J, Baca Y, Hinton A, Ahmad S, et al.
Gynecol Oncol
. 2024 Nov;
191:299-306.
PMID: 39500247
Background/objectives: Patients with recurrent or metastatic endometrial cancer (EC) have poor prognoses with limited therapeutic options following immunotherapy or immunochemotherapy treatments. Inhibitors of KRAS mutations (KRAS-mut) have shown efficacy in...
3.
Kuhn T, Ahmad S, Recio F, Awada A, McKenzie N, Kendrick J, et al.
Int J Gynecol Cancer
. 2024 Jun;
34(7):977-984.
PMID: 38830645
Objectives: External beam radiation with sensitizing platinum is the recommended therapy for locally advanced vulvar cancers not amenable to curative surgery and is associated with considerable acute and chronic side...
4.
Mutch D, Voulgari A, Chen X, Bradley W, Oaknin A, Perez Fidalgo J, et al.
Cancer
. 2024 Jan;
130(11):1940-1951.
PMID: 38288862
Background: This phase 1b study (ClinicalTrials.gov identifier NCT03695380) evaluated regimens combining PARP and MEK inhibition, with or without PD-L1 inhibition, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer (PSROC). Methods: Patients...
5.
Recio F, Scalise C, Loar P, Lumish M, Berman T, Peddada A, et al.
Gynecol Oncol
. 2024 Jan;
182:63-69.
PMID: 38262240
Introduction: Among uterine malignancies, endometrial cancer (EC) is the most common cancer of the female reproductive tract. Traditionally, risk stratification in EC is determined by standard clinicopathological risk factors. Although...
6.
Sefah K, Kilowski K, Gifford S, Grove A, Shaffer J, Bryan B, et al.
JCO Oncol Pract
. 2023 Oct;
19(12):1199-1205.
PMID: 37906723
Purpose: Infusion-related hypersensitivity reactions with paclitaxel are common despite the use of dexamethasone and diphenhydramine premedications. Paclitaxel titration protocols that may reduce reactions are empirically derived from clinical observations, and...
7.
Randall L, OMalley D, Monk B, Coleman R, Gaillard S, Adams S, et al.
Gynecol Oncol
. 2023 Oct;
178:161-169.
PMID: 37890345
Objective: This study assessed the efficacy, safety, and health-related quality of life (HRQoL) of the treatment regimen of dostarlimab, a programmed death-1 inhibitor, combined with niraparib, a poly (ADP-ribose) polymerase...
8.
McKenzie N, Ahmad S, Awada A, Kuhn T, Recio F, Holloway R
Life Sci
. 2023 Oct;
333:122178.
PMID: 37839778
High-grade serous ovarian cancer (HGSOC) is a particularly lethal malignancy that is prognostically influenced by the immune profile of the tumor microenvironment (TME). TME immune profiles have been sub-categorized according...
9.
Holloway R, Thaker P, Mendivil A, Ahmad S, Al-Niaimi A, Barter J, et al.
Int J Gynecol Cancer
. 2023 Sep;
33(9):1458-1463.
PMID: 37666539
Background: Treatment options for patients with platinum-resistant/refractory ovarian cancers are limited and only marginally effective. The development of novel, more effective therapies addresses a critical unmet medical need. Olvimulogene nanivacirepvec...
10.
Gwacham N, Kilowski K, Recio F, Awada A, Kuhn T, Zhu J, et al.
Gynecol Oncol
. 2023 Jun;
175:93-96.
PMID: 37329874
Background: Malignant peritoneal cytology in endometrial cancer (EC) is not considered an independent adverse prognostic factor for uterine-confined disease and is not a determinant factor in the International Federation of...